

**WHO Prequalification Programme**  
**WHO PUBLIC ASSESSMENT REPORT (WHOPAR)**

**[TB355 trade name]\***

Levofloxacin 750 mg tablets

[TB355 trade name], manufactured at Micro Labs Limited, Hosur, Tamil Nadu, India, was included in the WHO list of prequalified medicinal products for the prevention and treatment of tuberculosis on 19 November 2019.

[TB355 trade name] is indicated in combination with other tuberculosis medicines for the treatment of drug-resistant tuberculosis due to *Mycobacterium tuberculosis*. It is also indicated as monotherapy for the prevention of multidrug-resistant tuberculosis in persons at risk. Detailed information on the use of this product is described in the summary of product characteristics (SmPC), which can be found in this WHOPAR.

The active pharmaceutical ingredient of [TB355 trade name] is levofloxacin.

The efficacy and safety of levofloxacin is well established based on extensive clinical experience in the prevention and treatment of tuberculosis.

For details on the uses of this product and for side effects and warnings, see Part 4 of this WHOPAR (summary of product characteristics).

On the basis of data submitted and public information on the use of levofloxacin, the team of assessors advised that [TB355 trade name] is of acceptable quality, efficacy and safety to allow inclusion of [TB355 trade name] in the list of prequalified medicinal products.

**Summary of prequalification status for [TB355 trade name]:**

The table shows the status of relevant completed activities, including the dates of WHO internal quality assurance.

Initial acceptance	Date	Outcome
Status on PQ list	19 November 2019	listed
Pharmaceutical quality	29 October 2019	MR
Bioequivalence	01 November 2019	MR
Safety, efficacy	NA	NA
<b>GMP (re-)inspection</b>		
API	30 January 2015	MR
FPP	12 April 2019	MR
<b>GCP/GLP (re-)inspection</b>	NA	NA
API: active pharmaceutical ingredient FPP: finished pharmaceutical product GCP: good clinical practice [quality standard] GLP: good laboratory practice [quality standard] GMP: good manufacturing practice [quality standard] MR: meets requirements MR*: desk review (based on recent inspection reports) NA: not applicable, not available PQ: prequalification		

\* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.